What Aisling Capital Management LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1766721 · Filed Aug 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.6M |
| ±0% |
| $37.6M |
| 8% |
SNDXSyndax Pharmaceuticals Inc | 1.3M | ±0% | $28.8M | 6.1% |
CMPSCOMPASS Pathways plc | 1.4M | ±0% | $20.3M | 4.3% |
BCAXBicara Therapeutics Inc. | 568.9K | ±0% | $16.9M | 3.6% |
BBOTBridgeBio Oncology Therapeutics, Inc. | 1M | ±0% | $7.8M | 1.6% |
SRRKScholar Rock Holding Corp | 77K | ±0% | $4.2M | 0.9% |
URGNUroGen Pharma Ltd. | 108K | ±0% | $4M | 0.8% |
BMEABiomea Fusion, Inc. | 2M | ±0% | $3M | 0.6% |
ACRSAclaris Therapeutics, Inc. | 434.5K | ±0% | $2.3M | 0.5% |
EPRXEupraxia Pharmaceuticals Inc. | 325K | ±0% | $2.1M | 0.5% |
VTVTvTv Therapeutics Inc. | 50K | New | $1.9M | 0.4% |
MRKRMarker Therapeutics, Inc. | 325.4K | ±0% | $478.3K | 0.1% |
OKUROnKure Therapeutics, Inc. | 88.6K | ±0% | $404K | 0.1% |
